Details for Patent: 7,989,448

« Back to Dashboard

Which drugs does patent 7,989,448 protect, and when does it expire?

Patent 7,989,448 protects TAVALISSE and is included in one NDA.

This patent has thirty-eight patent family members in twenty-nine countries.

Summary for Patent: 7,989,448

Title:	Prodrugs of 2,4-pyrimidinediamine compounds and their uses
Abstract:	The present disclosure provides compounds of the following formula, and methods of using the compounds to inhibit cellular degranulation and to treat diseases associated therewith.
Inventor(s):	Rajinder Singh, Somasekhar Bhamidipati, Esteban Masuda
Assignee:	Rigel Pharmaceuticals Inc
Application Number:	US12/268,218
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 7,989,448

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Rigel Pharms	TAVALISSE	fostamatinib disodium	TABLET;ORAL	209299-001	Apr 17, 2018	AB	RX	Yes	No	7,989,448			Y		TREATMENT OF THROMBOCYTOPENIA IN ADULT PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA (ITP) WHO HAVE HAD AN INSUFFICIENT RESPONSE TO A PREVIOUS TREATMENT
Rigel Pharms	TAVALISSE	fostamatinib disodium	TABLET;ORAL	209299-002	Apr 17, 2018	AB	RX	Yes	Yes	7,989,448			Y		TREATMENT OF THROMBOCYTOPENIA IN ADULT PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA (ITP) WHO HAVE HAD AN INSUFFICIENT RESPONSE TO A PREVIOUS TREATMENT

International Family Members for US Patent 7,989,448

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1856135		301039	Netherlands
European Patent Office	1856135		CA 2020 00018	Denmark
European Patent Office	1856135		LUC00153	Luxembourg
European Patent Office	1856135		122020000021	Germany
European Patent Office	1856135		PA2020507	Lithuania
European Patent Office	1856135		132020000000046	Italy